EGFR and cancer: Our findings that gefitinib-induced down-regulation of CD47 promotes cancer cell phagocytosis in responsive cells and that establishment of gefitinib resistance reverts this response indicate a novel immune mechanism for EGFR TKI therapy, warranting further validation in preclinical and clinical studies.